Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.0
Journals
Children
Special Issues
Pediatric Blood Diseases and Blood Transfusion Treatment
share announcement

Pediatric Blood Diseases and Blood Transfusion Treatment

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".

Deadline for manuscript submissions: 1 June 2025 | Viewed by 3260

Special Issue Editor

Dr. Stavroula Parastatidou

E-Mail Website
Guest Editor
Neonatal Intensive Care Unit, “Elena Venizelou” Maternity Hospital, 11521 Athens, Greece
Interests: neonatal care; neoantal hematology; viscoelastic tests; pediatric hematology; breastfeeding; neonatal respiratory support

Special Issue Information

Dear Colleagues,

Pediatric blood diseases include a wide variety of conditions, either congenital or acquired, that present during early life. Their manifestations range from mild to life-threatening, with a possibly significant impact on children’s quality of life. Novel therapeutic strategies have emerged for some of these disorders; however, the transfusion of blood products remains the mainstay of management for many hematologic conditions in children. Although often life-saving and irreplaceable, transfusions may be associated with serious complications, and important challenges are still related to their administration. Further research is required to elucidate the relevant knowledge gaps.  

This Special Issue aims to highlight the current practices, address issues and explore future directions in the field of transfusion treatment for pediatric blood disorders. Both original research and review articles are welcome.

Dr. Stavroula Parastatidou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • congenital blood disorders
  • anemia
  • red blood cell disorders
  • platelet disorders
  • coagulation disorders
  • white blood cell disorders
  • red blood cell transfusions
  • platelet transfusions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1510 KiB  
Article
Intravenous Sodium Ferric Gluconate Complex for Hospitalized Pediatric Patients with Iron Deficiency Anemia
by Felicia White, Noelle Polakowski, Elena Merlington, Mara Leimanis, Brooke Dudick, Jessica Parker, Ashley Jousma, Alexander Loji, Jeffrey Hanson, Monica Arney and Brian Boville
Children 2025, 12(2), 189; https://doi.org/10.3390/children12020189 - 5 Feb 2025
Viewed by 844
Abstract
Background/Objectives: Iron deficiency anemia is common in the pediatric population. Red blood cell transfusions, a common acute treatment, pose well-recognized risks including lung injury, circulatory overload, and immune dysfunction. Intravenous iron, specifically sodium ferric gluconate complex (SFGC), is a potential alternative, however investigation [...] Read more.
Background/Objectives: Iron deficiency anemia is common in the pediatric population. Red blood cell transfusions, a common acute treatment, pose well-recognized risks including lung injury, circulatory overload, and immune dysfunction. Intravenous iron, specifically sodium ferric gluconate complex (SFGC), is a potential alternative, however investigation on its use in hospitalized children is lacking. This study aims to describe the physiologic response via change in hematologic values to cumulative dose of SFGC, investigate the effect of cumulative dosing on the amount of RBC transfusions received, and comment on its safety. Methods: This is a retrospective investigation of pediatric patients with iron deficiency who received SFGC during their admission to the Helen DeVos Children’s Hospital between 2016 and 2018 (N = 85). Results: A total of 258 doses of intravenous SFGC were provided to 85 patients. The average pre-treatment serum hemoglobin was 8.73 ± 1.33, and 7 days post-treatment this increased to 10.41 ± 1.43. Mean corpuscular volume, ferritin, serum ion, total iron binding capacity, reticulocyte percentage, and reticulocyte hemoglobin all increased 7 days post-treatment, as would be suspected, but without any statistically significant difference between hematologic outcomes and cumulative dose of SFGC. Our study did not reveal any correlation between the cumulative dose of SFGC administered and the amount of RBC transfusions received. Only one adverse event was recorded. Conclusions: Our results complement the trend of increased use and emerging evidence of favorable safety profiles of IV iron in the pediatric population. This descriptive investigation revealed that administering higher cumulative doses of SFGC provided no further benefits in terms of hematologic response or RBC transfusion administration. Full article
(This article belongs to the Special Issue Pediatric Blood Diseases and Blood Transfusion Treatment)
►▼ Show Figures

Figure 1

8 pages, 326 KiB  
Article
Asthma Is an Independent Risk Factor for Acute Chest Syndrome in Children with Sickle Cell Disease in French Guiana
by Gabriel Bafunyembaka, Mathieu Nacher, Chimène Maniassom, Archippe Muhandule Birindwa and Narcisse Elenga
Children 2024, 11(12), 1541; https://doi.org/10.3390/children11121541 - 19 Dec 2024
Viewed by 651
Abstract
Background/Objectives: The overall incidence of asthma in children with sickle cell disease in French Guiana is unknown. Asthma is common in children with sickle cell disease and is associated with increased morbidity and mortality. This study aimed to describe the impact of asthma [...] Read more.
Background/Objectives: The overall incidence of asthma in children with sickle cell disease in French Guiana is unknown. Asthma is common in children with sickle cell disease and is associated with increased morbidity and mortality. This study aimed to describe the impact of asthma on the occurrence of acute chest syndrome in children with sickle cell disease who were followed up in French Guiana. Methods: We performed a multicenter nested case-control study between January 2012 and December 2022. Our study population consisted of children, aged between 6 months and 18 years, who were diagnosed with sickle cell disease at birth and hospitalized at least once for acute chest syndrome during the study period. Results: A total of 588 children were followed up for sickle cell disease. Of these, 390 had sickle cell disease, 180 had SC, and 18 had Sβ + thalassemia. Of the 390-sickle cell disease, we identified 35 who also had asthma, giving an estimated prevalence of asthma of 8.9% among children with sickle cell disease in French Guiana. Only asthma was significantly associated with acute chest syndrome (p < 0.001). Conclusions: The prevalence of asthma in children with sickle cell disease is underestimated. Asthma is an independent risk factor for acute chest syndrome. Given the seriousness of asthma in children with sickle cell disease, systematic screening for asthma in children with sickle cell disease has been implemented. This screening, which will be evaluated after one year, will help to better characterize asthmatic children with sickle cell disease and improve their care. Full article
(This article belongs to the Special Issue Pediatric Blood Diseases and Blood Transfusion Treatment)
►▼ Show Figures

Figure 1

9 pages, 702 KiB  
Article
Experience with Pediatric Chronic Immune Thrombocytopenia over 30 Years in the Era before Eltrombopag
by Begum S. Koc, Gul Nihal Ozdemir, Javid Alakbarli, Hilmi Apak and Tiraje Celkan
Children 2024, 11(9), 1051; https://doi.org/10.3390/children11091051 - 28 Aug 2024
Viewed by 1219
Abstract
Background: There is limited information on the natural course of chronic ITP in children. We aimed to evaluate the clinical and demographic characteristics of children with chronic ITP in the era before the availability of eltrombopag. Methods: A total of 86 children with [...] Read more.
Background: There is limited information on the natural course of chronic ITP in children. We aimed to evaluate the clinical and demographic characteristics of children with chronic ITP in the era before the availability of eltrombopag. Methods: A total of 86 children with chronic ITP between 1978–2014 were included. Demographic findings, laboratory results, clinical signs, bleeding scores, response time and time of complete remission were recorded. Results: The male/female ratio was 1.09, and median follow-up time was 3 years (range: 1.5–17 years). The median age at diagnosis of chronic ITP was 7 years (range: 2–17), and the median initial platelet count was 10 × 109/L (range: 1–66 × 109/L). Petechiae/ecchymoses were the most common clinical sign (86%) and followed by mucosal bleeding (39.5%). Severe bleeding was seen in 5% of the patients. None of them had intracranial hemorrhage. Twenty patients underwent splenectomy, and the rate of complete remission was 70%. Spontaneous complete remission was seen in 29% of the patients, and the median time to spontaneous complete remission was 3 years. Conclusions: Our study showed that almost one-third of patients with chronic ITP experienced spontaneous complete remission in an average of 3 years, and splenectomy provided satisfactory results in severe cases. This study demonstrates the natural history of chronic ITP in childhood before the era of eltrombopag. Full article
(This article belongs to the Special Issue Pediatric Blood Diseases and Blood Transfusion Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop